Loading
Chemotherapy-induced Organ Toxicity Mitigation · Journal article
Indonesian Journal of Innovation Multidisipliner Research · August 13, 2026
Raises a question worth testing. It does not answer one.
This narrative review evaluates the molecular mechanisms by which Nigella sativa–derived bioactive constituents, particularly thymoquinone, may sensitize cancer cells to conventional therapies in preclinical models. While thymoquinone modulates multiple signaling pathways and has enhanced chemotherapy, radiotherapy, and targeted agents in experimental systems, the evidence remains mechanistic and exploratory, constrained by poor bioavailability, chemical instability, and absence of clinical translation.
Narrative review. Published literature on Nigella sativa constituents and cancer resistance mechanisms; no enrolled human or animal subjects.. Intervention: Nigella sativa–derived bioactive constituents, with emphasis on thymoquinone, evaluated for adjuvant potential in cancer therapy.. Compared with: Conventional cancer therapies (chemotherapy, radiotherapy, targeted agents) in preclinical models..
Thymoquinone modulates PI3K/Akt/mTOR, JAK/STAT, NF-κB, and Wnt/β-catenin signaling in experimental models Thymoquinone has enhanced the effects of chemotherapy, radiotherapy, and selected targeted agents in several experimental models Treatment responses vary according to cancer type, dose, formulation, therapeutic combination, and microenvironmental conditions
Thymoquinone bioavailability, chemical stability, and long-term safety remain inadequately evaluated.
These findings do not yet support clinical use of Nigella sativa constituents as adjuvants to cancer therapy. Thymoquinone and related compounds are presented as research candidates requiring pharmacokinetic optimization, standardized formulations, and well-designed early-phase clinical studies before clinical translation can be considered.
A narrative review of preclinical mechanistic evidence for plant-derived compounds in cancer models, raising questions about adjuvant potential rather than answering them with clinical evidence.
As stated by the source record.
These findings do not yet support clinical use of Nigella sativa constituents as adjuvants to cancer therapy. Thymoquinone and related compounds are presented as research candidates requiring pharmacokinetic optimization, standardized formulations, and well-designed early-phase clinical studies before clinical translation can be considered.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Resistance to cancer therapy remains a major cause of treatment failure, tumor recurrence, and disease progression because malignant cells can adapt through interconnected mechanisms involving prosurvival signaling, apoptosis suppression, drug efflux, epithelial–mesenchymal plasticity, cancer stemness, and the tumor microenvironment. This narrative review evaluates the molecular basis and adjuvant potential of Nigella sativa–derived bioactive constituents in overcoming resistance to conventional cancer therapies. Relevant literature was identified from Scopus, PubMed, Web of Science, ScienceDirect, and Google Scholar, with emphasis on resistance-related mechanisms, treatment sensitization, and combination-therapy studies. Among the identified constituents, thymoquinone has the strongest preclinical evidence. It modulates PI3K/Akt/mTOR, JAK/STAT, NF-κB, and Wnt/β-catenin signaling; enhances mitochondrial apoptosis; regulates ABC drug transporters; and influences autophagy, epithelial–mesenchymal transition, and cancer stem-cell properties. Thymoquinone has also enhanced the effects of chemotherapy, radiotherapy, and selected targeted agents in several experimental models, although treatment responses vary according to cancer type, dose, formulation, therapeutic combination, and microenvironmental conditions. Evidence for α-hederin, thymohydroquinone, dithymoquinone, thymol, and carvacrol remains comparatively limited, particularly in validated models of established treatment resistance. Clinical translation is further constrained by poor thymoquinone solubility and bioavailability, chemical instability, phytochemical variability, limited pharmacokinetic data, and insufficient evaluation of long-term safety and drug interactions. Overall, N. sativa-derived constituents, particularly thymoquinone, represent promising multi-target adjuvant candidates rather than alternatives to established cancer treatments. Future research should prioritize chemically standardized preparations, resistant cancer models, quantitative combination analyses, clinically relevant dosing, and well-designed pharmacokinetic, toxicological, and early-phase clinical studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.